Oral Progestins in Hormonal Contraception: Importance and Future Perspectives of a New Progestin Only-Pill Containing 4 mg Drospirenone.
Level 5 - mechanism / opinion, no new human data
Narrative review summarizing drug development and clinical trials without systematic search methodology
PubMed 34565826 · doi:10.1055/a-1471-4408
What was done
This narrative review summarizes the pharmacological properties, clinical development program, contraceptive effectiveness, and safety profile of an estrogen-free progestin-only pill containing 4 mg drospirenone administered in a 24-day active / 4-day hormone-free regimen.
What was found
The abstract reports that drospirenone has an elimination half-life of 30 to 34 hours and that experimental 24-hour pill intake delays maintain ovulation inhibition. No specific quantitative rates for pregnancy, bleeding patterns, or cardiovascular events are provided in the abstract.
Why it matters
This formulation provides an estrogen-free oral contraceptive option designed to improve bleeding control and offer greater forgiveness for missed pills compared to traditional progestin-only pills.
Limits
As a narrative review, it lacks systematic search methodology and meta-analytic synthesis. The abstract provides no numerical data, sample sizes, trial characteristics, or quantitative adverse event rates.
Cited by
- supports Slynd is a progestin-only birth control pill that is anti-androgenic.